Literature DB >> 26341989

The reproducibility and responsiveness of the lung clearance index in bronchiectasis.

Lizzie Grillo1, Samantha Irving2, David M Hansell3, Arjun Nair4, Bertrand Annan4, Simon Ward5, Diana Bilton6, Eleanor Main7, Jane Davies8, Andrew Bush8, Robert Wilson6, Michael R Loebinger9.   

Abstract

Lung clearance index (LCI) is a potential clinical outcome marker in bronchiectasis. Its responsiveness to therapeutic intervention has not been determined. This study evaluates its responsiveness to a session of physiotherapy and intravenous antibiotic treatment of an exacerbation.32 stable and 32 exacerbating bronchiectasis patients and 26 healthy controls were recruited. Patients had LCI and lung function performed before and after physiotherapy on two separate occasions in the stable patients and at the beginning and end of an intravenous antibiotic course in the exacerbating patients.LCI was reproducible between visits in 25 stable patients, with an intraclass correlation of 0.978 (0.948, 0.991; p<0.001). There was no significant difference in LCI (mean±sd) between stable 11.91±3.39 and exacerbating patients 12.76±3.47, but LCI was significantly higher in both bronchiectasis groups compared with healthy controls (7.36±0.99) (p<0.001). Forced expiratory volume in 1 s improved after physiotherapy, as did alveolar volume after intravenous antibiotics, but LCI did not change significantly.LCI is reproducible in stable bronchiectasis but unlike conventional lung function tests, is unresponsive to two short-term interventions and hence is unlikely to be a useful clinical tool for short-term acute assessment in these patients. Further evaluation is required to establish its role in milder disease and in the evaluation of long-term interventions.
Copyright ©ERS 2015.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26341989     DOI: 10.1183/13993003.00152-2015

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  10 in total

1.  Multiple-Breath Washout Outcome Measures in Adults with Bronchiectasis.

Authors:  Katherine O'Neill; Gokul R Lakshmipathy; Curtis Neely; Denise Cosgrove; Kathryn Ferguson; Rebecca McLeese; Adam T Hill; Michael R Loebinger; Mary Carroll; James D Chalmers; Timothy Gatheral; Chris Johnson; Anthony De Soyza; John R Hurst; Ian Bradbury; Joseph S Elborn; Judy M Bradley
Journal:  Ann Am Thorac Soc       Date:  2022-09

2.  Multiple breath washout testing in adults with pulmonary disease and healthy controls - can fewer measurements eventually be more?

Authors:  Frederik Trinkmann; Johannes Götzmann; Daniel Saur; Michele Schroeter; Katharina Roth; Ksenija Stach; Martin Borggrefe; Joachim Saur; Ibrahim Akin; Julia D Michels
Journal:  BMC Pulm Med       Date:  2017-12-11       Impact factor: 3.317

Review 3.  The Likelihood of Preventing Respiratory Exacerbations in Children and Adolescents with either Chronic Suppurative Lung Disease or Bronchiectasis.

Authors:  Kerry-Ann F O'Grady; Keith Grimwood
Journal:  Front Pediatr       Date:  2017-03-24       Impact factor: 3.418

4.  4-week daily airway clearance using oscillating positive-end expiratory pressure versus autogenic drainage in bronchiectasis patients: a randomised controlled trial.

Authors:  Galit Livnat; Naama Yaari; Nili Stein; Lea Bentur; Moneera Hanna; Maya Harel; Yochai Adir; Michal Shteinberg
Journal:  ERJ Open Res       Date:  2021-11-08

Review 5.  Monitoring disease progression in childhood bronchiectasis.

Authors:  Kathryn A Ramsey; André Schultz
Journal:  Front Pediatr       Date:  2022-09-16       Impact factor: 3.569

6.  Maximal mid-expiratory flow is a surrogate marker of lung clearance index for assessment of adults with bronchiectasis.

Authors:  Wei-Jie Guan; Jing-Jing Yuan; Yong-Hua Gao; Hui-Min Li; Jin-Ping Zheng; Rong-Chang Chen; Nan-Shan Zhong
Journal:  Sci Rep       Date:  2016-06-24       Impact factor: 4.379

7.  Residual volume/total lung capacity ratio confers limited additive significance to lung clearance index for assessment of adults with bronchiectasis.

Authors:  Wei-Jie Guan; Jing-Jing Yuan; Yan Huang; Hui-Min Li; Rong-Chang Chen; Nan-Shan Zhong
Journal:  PLoS One       Date:  2017-09-08       Impact factor: 3.240

8.  Bronchiectasis: working together for better evidence.

Authors:  James D Chalmers
Journal:  Lancet Respir Med       Date:  2015-12       Impact factor: 30.700

9.  Multiple breath washout in bronchiectasis clinical trials: is it feasible?

Authors:  Katherine O'Neill; Kathryn Ferguson; Denis Cosgrove; Michael M Tunney; Anthony De Soyza; Mary Carroll; James D Chalmers; Timothy Gatheral; Adam T Hill; John R Hurst; Christopher Johnson; Michael R Loebinger; Gerhild Angyalosi; Charles S Haworth; Renee Jensen; Felix Ratjen; Clare Saunders; Christopher Short; Jane C Davies; J Stuart Elborn; Judy M Bradley
Journal:  ERJ Open Res       Date:  2020-10-13

10.  The validity of shortened multiple-breath washout testing using sulfur hexafluoride in the assessment of patients with COPD.

Authors:  Enya Daynes; Neil Greening; John Owers-Bradley; Sally J Singh; Salman Siddiqui
Journal:  ERJ Open Res       Date:  2021-08-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.